Lisa Schnirring

Study sheds more light on delamanid role in treating MDR-TB

A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo, but that it was safe and well tolerated.

Read More →

Page 1 of 1 · Total posts: 1